[China FIC Drug] Influenza A virus RNA Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025

Drug Name: Onradivir 

Drug Modality: Small Molecule

Drug Target:  Influenza A virus RNA Polymerase PB2 Inhibitor

Developed By：Guangdong Raynovent Biotech (subsidiary of Guangdong Zhongsheng Pharmaceutical)

Approved Date: 2025-05 by China NMPA

Indication: Influenza A

Dosage Form and Strength: Tablets, 200 mg

.

.

Product Code: ZSP1273

Chinese Name: 昂拉地韦